Nebivolol

Usual Dosing (Adults)

CLINICAL PHARMACOLOGY
Nebivolol is a beta-adrenergic receptor blocking agent. In extensive metabolizers (most of the population) and at doses less than or equal to 10 mg, nebivolol is preferentially beta1 selective. In poor metabolizers and at higher doses, nebivolol inhibits both beta1 - and beta2 - adrenergic receptors. Nebivolol lacks intrinsic sympathomimetic and membrane stabilizing activity at therapeutically relevant concentrations. At clinically relevant doses, BYSTOLIC does not demonstrate alpha1-adrenergic receptor blockade activity. Various metabolites, including glucuronides, contribute to beta-blocking activity.

INDICATIONS AND USAGE
Hypertension: BYSTOLIC is indicated for the treatment of hypertension. BYSTOLIC may be used alone or in combination with other antihypertensive agents.

DOSAGE AND ADMINISTRATION
Hypertension:
The dose of BYSTOLIC must be individualized to the needs of the patient. For most patients, the recommended starting dose is 5 mg once daily, with or without food, as monotherapy or in combination with other agents. For patients requiring further reduction in blood pressure, the dose can be increased at 2-week intervals up to 40 mg. A more frequent dosing regimen is unlikely to be beneficial.

Renal Dosing

Renal Impairment:
In patients with severe renal impairment (ClCr less than 30 mL/min) the recommended initial dose is 2.5 mg once daily; titrate up slowly if needed.

Hemodialysis

BYSTOLIC has not been studied in patients receiving dialysis.

Reference(s)

National Institutes of Health, U.S. National Library of Medicine, DailyMed Database.
Provides access to the latest drug monographs submitted to the Food and Drug Administration (FDA). Please review the latest applicable package insert for additional information and possible updates. A local search option of this data can be found here.